Related by context. All words. (Click for frequent words.) 72 estrogen receptor positive 72 HER2 positive 69 HER2 negative 69 progesterone receptor negative 68 estrogen receptor negative 66 hormone receptor negative 66 estrogen receptor ER 66 lobular carcinoma 66 HER2 positive metastatic breast 65 situ LCIS 65 EGFR mutation 65 recurrent NSCLC 64 HER2 positive tumors 64 HER2 + 64 neoadjuvant chemotherapy 63 breast carcinoma 63 fallopian tube carcinoma 63 operable breast cancer 63 advanced unresectable 63 epithelial ovarian 63 metastatic carcinoma 63 ErbB2 positive 62 adjuvant therapy 62 castration resistant prostate cancer 62 metastatic breast cancer 62 advanced hepatocellular carcinoma 62 Squamous 62 cisplatin chemotherapy 62 NSCLC 62 pancreatic adenocarcinoma 62 metastatic HER2 negative 62 advanced adenomas 62 metastatic colorectal carcinoma 62 metastatic renal cell carcinoma 62 situ CIS 62 resectable 62 neoadjuvant 62 non squamous NSCLC 62 unresectable tumors 62 estrogen receptor progesterone receptor 62 stage IIIb IV 62 metastatic gastric 61 nonsmall cell lung cancer 61 luteinizing hormone releasing 61 HER2 receptor 61 invasive ductal 61 atypical hyperplasia 61 epithelial ovarian cancer 61 endometrial cancers 61 relapsed ovarian cancer 61 neoadjuvant therapy 61 recurrent prostate cancer 61 ductal carcinomas 61 distant metastasis 61 preoperative chemotherapy 61 basal cell carcinoma BCC 61 malignant pleural mesothelioma 61 HER2 positive breast cancer 61 axillary lymph nodes 61 invasive lobular carcinoma 61 adjuvant radiotherapy 61 Adjuvant chemotherapy 61 distant metastases 61 unresectable 61 BRCA1 mutation carriers 61 stage IIIB 61 BRAF mutation 61 metastatic RCC 60 BRCA2 mutations 60 gastrointestinal stromal tumors 60 recurrent metastatic 60 recurrent ovarian 60 nonmetastatic 60 atypia 60 HER2 expression 60 cervical intraepithelial neoplasia 60 hepatic metastases 60 recurrent ovarian cancer 60 adenocarcinoma 60 neoadjuvant treatment 60 gemcitabine chemotherapy 60 hepatocellular cancer 60 K ras mutations 60 advanced adenoma 60 Her2 60 invasive breast cancer 60 node metastases 60 lobular cancer 60 renal cell carcinoma 60 recurrent glioblastoma multiforme 60 breast cancers 60 mucinous 60 metastatic 60 HNSCC 60 ductal breast cancer 60 epithelial tumors 60 adenocarcinomas 60 sorafenib tablets 60 HER2 positive cancers 60 cetuximab 59 serous ovarian cancer 59 chlorambucil 59 HER2 amplification 59 Irinotecan 59 curative resection 59 metastatic prostate cancer 59 PCa 59 HER2 overexpression 59 CIN3 59 whose tumors overexpress 59 hepatocellular carcinoma HCC 59 prostate cancer CRPC 59 atypical ductal hyperplasia 59 histologically confirmed 59 HGPIN 59 poorer prognosis 59 invasive ductal carcinoma 59 colorectal gastric 59 KRAS mutations 59 contralateral breast 59 KRAS status 59 neoplasia 59 colorectal liver metastases 59 ovarian carcinoma 59 LHRH receptor positive 59 HER2 ErbB2 59 adenoma 59 KRAS mutations occur 59 metastatic colorectal cancer 59 advanced HER2 positive 59 tamoxifen therapy 59 metastatic colorectal 59 endocrine therapy 59 Recurrence Score 59 invasive lobular 59 adjuvant chemotherapy 59 chemotherapy cisplatin 59 HER-2/neu 59 TOP2A 59 NMIBC 59 unresectable locally advanced 59 ductal carcinoma 59 taxane chemotherapy 59 liver metastases 59 hormone therapy estrogen 59 adjuvant radiation 59 urothelial carcinoma 59 gefitinib 59 platinum refractory 59 FOLFOX6 59 colorectal carcinoma 59 Adjuvant Treatment 59 refractory multiple myeloma 59 lymph node metastases 59 endometrial carcinoma 58 bladder cancers 58 autoantibody positive 58 metastatic pancreatic 58 prostate carcinoma 58 mCRC patients 58 FASLODEX 58 Papillary 58 metastatic NSCLC 58 lobular carcinomas 58 clinically localized prostate 58 micrometastases 58 gastrointestinal stromal tumor 58 sentinel lymph node biopsy 58 metastatic castration resistant 58 pegylated liposomal doxorubicin 58 GISTs 58 vandetanib 58 mRCC 58 cervical carcinoma 58 CaP 58 chemoradiotherapy 58 locoregional recurrence 58 differentiated thyroid 58 premenopausal 58 pT2 58 gefitinib Iressa 58 dasatinib Sprycel ® 58 BRCA deficient 58 breast carcinomas 58 metastatic GIST 58 fallopian tube cancers 58 Her2 positive 58 castration resistant 58 alkylating agents 58 gemcitabine Gemzar 58 BCG refractory 58 pCR 58 B CLL 58 GnRH agonists 58 tumor histology 58 colorectal adenoma 58 FOLFOX regimen 58 non resectable 58 breast tumors 58 SHPT 58 HBeAg negative 58 brain metastases 58 bevacizumab Avastin 58 Carcinoma 58 trastuzumab 58 Her2/neu 58 metastatic HER2 positive 58 adriamycin 58 squamous cell 58 cell carcinoma 58 anthracycline taxane 58 medullary thyroid cancer 58 progesterone receptor PR 58 goserelin 58 advanced NSCLC 58 cT3 prostate cancer 58 radiation chemoradiation 58 KRAS wild 58 dasatinib 58 ovarian lung 58 Adenocarcinoma 58 AVASTIN 58 pemetrexed 58 metastatic bladder 58 carcinomas 58 chemoresistant 58 EGFR mutations 58 aromatase inhibitor 57 peritoneal cancer 57 relapsed SCLC 57 mycosis fungoides 57 endometrial hyperplasia 57 Neoadjuvant 57 prostate cancers 57 renal tumors 57 ductal cancer 57 carcinoid tumors 57 letrozole Femara 57 precursor lesions 57 EBRT 57 ADPKD 57 medically inoperable 57 biochemical recurrence 57 contralateral breast cancer 57 histologic subtype 57 tumor recurrence 57 EGFR mutation positive 57 gastric cancer 57 anastrozole 57 ASCUS 57 Metastatic 57 metastatic colon cancer 57 renal cell carcinomas 57 chemoradiation 57 5 Fluorouracil 57 XELOX 57 alkylating agent 57 invasive carcinoma 57 external beam radiotherapy 57 lymph node involvement 57 chemoradiation therapy 57 tumors GIST 57 adenomatous 57 Lenalidomide 57 BRCA mutation carriers 57 anastrazole 57 small lymphocytic lymphoma 57 HER2/neu 57 rectal cancers 57 Carcinoid tumors 57 metastatic disease 57 Taxotere ® 57 hormone receptor status 57 metastatic HER 57 stage IIIA 57 lenalidomide Revlimid R 57 Ductal carcinoma 57 locoregional 57 metastatic neuroendocrine tumors 57 histologically proven 57 Erlotinib 57 SCCHN 57 pancreatic NET 57 carcinoma 57 erlotinib Tarceva ® 57 taxane therapy 57 lobular breast cancer 57 carboplatin paclitaxel 57 colorectal cancers 57 FOLFIRI 57 colorectal polyp 57 follicular NHL 57 hormonal therapy 57 metastatic malignant 57 antiangiogenic therapy 57 BRCA2 mutation carriers 57 HER2 positive breast 57 mutated KRAS gene 57 prostate cancer CaP 57 colorectal carcinomas 57 irinotecan chemotherapy 57 gastrointestinal stromal tumors GIST 57 mesotheliomas 57 tamoxifen Nolvadex ® 57 pleural mesothelioma 57 Exemestane 57 superficial bladder cancer 57 nonsquamous histology 57 B7 H3 57 HRPC 57 ARB telmisartan 57 metastatic hormone refractory 57 androgen deprivation 57 peritoneal carcinomatosis 57 CIN2 + 57 cytoreduction 57 leukemia AML 57 adenomatous polyps 57 poly ADP ribose polymerase 57 Pemetrexed 57 salpingo oophorectomy 57 gastric cancers 57 situ DCIS 57 leiomyomas 57 5-FU/LV 57 squamous histology 57 liver metastasis 56 urothelial bladder cancer 56 distal colon cancer 56 HER2 56 recurrent VTE 56 localized prostate cancer 56 premenopausal women 56 PegIntron 56 ABCB1 56 NOLVADEX 56 hormone refractory prostate cancer 56 Kit CD# positive 56 capecitabine Xeloda 56 colorectal pancreatic 56 Metastatic breast cancer 56 metastatic pancreatic cancer 56 advanced metastatic prostate 56 letrozole 56 Capecitabine 56 pT3 56 paricalcitol 56 fibroadenomas 56 Metastatic Breast Cancer 56 non metastatic osteosarcoma 56 estrogen receptor 56 malignant pleural mesothelioma MPM 56 histological subtype 56 cystectomy 56 T1a 56 Paraplatin ® 56 metastatic castrate resistant 56 Trastuzumab 56 uterine cancers 56 pertuzumab 56 histologies 56 oophorectomy 56 Fludarabine 56 cisplatin 56 radical nephrectomy 56 cetuximab Erbitux 56 sorafenib Nexavar 56 lung adenocarcinoma 56 NSCLC tumors 56 BRCA mutations 56 hepatocellular carcinoma 56 colorectal cancer 56 myelofibrosis polycythemia vera 56 gastric adenocarcinoma 56 Peginterferon 56 gastrointestinal stromal tumor GIST 56 nonmelanoma skin cancers 56 Vandetanib 56 BRCA2 mutation 56 bone metastases 56 castrate resistant prostate cancer 56 bendamustine 56 ER CHOP 56 axillary dissection 56 relapsed MM 56 hormone LHRH 56 Estrogen Receptor 56 SPINK1 56 BRAF V#E mutation 56 castrate resistant 56 ritonavir boosted 56 sarcomatoid 56 breast cancer recurrence 56 Advanced Renal Cell 56 metastases 56 lymph node dissection 56 axillary nodes 56 biochemical relapse 56 resistant ovarian cancer 56 AstraZeneca Arimidex 56 hepatocellular carcinomas 56 basal cell nevus syndrome 56 lung pancreatic 56 evaluating T DM1 56 thromboembolic events 56 leukemia CLL 56 Folfox 56 HER2 positivity 56 trabectedin 56 cutaneous melanoma 56 pancreatic lung 56 CYT# potent vascular disrupting 56 pulmonary metastases 56 oral clodronate 56 eribulin 56 hypercalcemia 56 bone metastasis 56 Soft Tissue Sarcoma 56 mutated K ras 56 sunitinib malate 56 xanthine oxidase inhibitor 56 cisplatin resistant 56 CC genotype 56 DOXIL ® 56 cutaneous squamous cell carcinoma 56 Follicular Lymphoma 56 osteosarcomas 56 resistant hormone refractory 56 chemotherapy regimens 56 overexpress HER2 56 ERBB2 56 flutamide 56 grade cervical intraepithelial 56 endometriosis ovarian cysts 56 secondary hyperparathyroidism 56 dacarbazine 56 systemic lupus erythematosus 56 EpCAM 56 xenograft models 56 BRAF mutations 56 prognostic indicator 56 Basal cell 56 temsirolimus 56 liposomal doxorubicin 56 sentinel node biopsy 56 Metastatic Colorectal Cancer 56 metastatic cancer 56 histologic subtypes 56 cell carcinomas 56 neoplasia PIN 56 breast endometrial 56 ovarian breast 56 follicular lymphoma FL 56 androgen independent 56 HER2 amplified 56 docetaxel chemotherapy 56 PSADT 55 breast pancreatic 55 KRAS mutation 55 tamoxifen 55 lymphovascular invasion 55 unresectable stage 55 carcinoma HCC 55 Alemtuzumab 55 ZACTIMA 55 Diffuse Large B 55 completely resected 55 FOLFIRI alone 55 fluvastatin 55 papillary renal cell carcinoma 55 uterine ovarian 55 capecitabine 55 androgen deprivation therapy 55 malignant lymphoma 55 Uterine cancer 55 lymphadenectomy 55 carcinoid 55 symptomatic fibroids 55 Surgical resection 55 trastuzumab Herceptin 55 prostate adenocarcinoma 55 zoledronic acid 55 primary peritoneal 55 lymphoproliferative disorders 55 receptor tyrosine kinase inhibitor 55 endometrial kidney 55 infusional 5-FU/LV 55 Herceptin trastuzumab 55 dacarbazine DTIC 55 soft tissue sarcomas 55 macroalbuminuria 55 endometrial cancer 55 symptomatic BPH 55 axillary node dissection 55 anaplastic 55 skeletal metastases 55 Hurthle cell 55 radiotherapy RT 55 Castration Resistant Prostate Cancer 55 lymph node metastasis 55 Postmenopausal Women 55 postoperative chemotherapy 55 catheter angiography 55 hormonal therapies 55 fludarabine 55 bevacizumab Avastin ® 55 undergone radical prostatectomy 55 Adjuvant therapy 55 paclitaxel cisplatin 55 non squamous 55 selective modulator 55 bladder ovarian 55 colorectal cancer CRC 55 adjuvant endocrine therapy 55 diffuse gastric 55 colorectal lung 55 paclitaxel carboplatin 55 SLNB 55 epithelioid 55 bicalutamide 55 intestinal polyps 55 DOXIL 55 intravenous bisphosphonates 55 pelvic lymphadenectomy 55 nodal metastasis 55 achieved ACR# 55 orchiectomy 55 subependymal giant cell 55 gastric carcinoma 55 T1c 55 interferon IFN 55 CTAP# Capsules 55 bilateral oophorectomy 55 BRCA2 carriers 55 Metastatic Prostate Cancer 55 Radical prostatectomy 55 bevacizumab 55 intestinal metaplasia 55 polyp recurrence 55 follicular lymphoma 55 glioblastoma multiforme GBM 55 rs# [002] 55 pneumonectomy 55 mCRC 55 Anastrozole 55 pancreatic neuroendocrine tumors 55 FOLFOX4 55 pancreatic ovarian 55 FLT3 55 myelodysplastic syndrome MDS 55 androgen suppression 55 breast cancer subtypes 55 EGFR 55 underwent surgical resection 55 metastatic renal cell 55 EGFR mutant 55 cyclophosphamide methotrexate 55 panobinostat 55 nilotinib Tasigna ® 55 metastatic adenocarcinoma 55 axillary lymph node dissection 55 mutated BRCA1 55 chemotherapeutic agent 55 nonalcoholic steatohepatitis NASH 55 standard chemotherapy regimens 55 interferon alfa 2b 55 testicular germ cell 55 refractory metastatic 55 ARIMIDEX 55 Bevacizumab 55 cytotoxic therapy 55 epirubicin 55 myeloproliferative diseases 55 pegylated interferon alfa 2a 55 tibolone 55 Leukemias 55 Epidermal Growth Factor Receptor 55 Amrubicin 55 monoclonal antibody IgG1 Mab 55 prognostic variables 55 invasive ductal carcinomas 55 Malignant Melanoma 55 minimally symptomatic 55 vertebral fracture 55 hip BMD 55 cell acute lymphoblastic 55 prognostic factor 55 Platinol ® cisplatin 55 prostate pancreatic 55 pheochromocytoma 55 LHRH agonists 55 severe neutropenia 55 total thyroidectomy 55 BRAF V#E 55 trastuzumab Herceptin R 55 imatinib 55 GnRH agonist 55 postmenopausal women 55 Cisplatin 55 Nexavar ® 55 thromboembolisms 55 cyclin E 54 Peginterferon alfa 2b 54 tamoxifen citrate 54 bowel cancers 54 carcinoembryonic antigen CEA 54 Torisel 54 relapsed refractory multiple myeloma 54 neoplasms 54 EGFR inhibitors 54 colon cancers 54 raloxifene Evista 54 colorectal neoplasms 54 Doxil ® 54 tumor subtypes 54 eribulin mesylate 54 alvespimycin 54 5FU 54 CrCl 54 CIMZIA ™ 54 metachronous 54 lymph node removal 54 non Hodgkin lymphomas 54 nonfasting triglyceride levels 54 imatinib Gleevec ® 54 EGFR HER2 54 Cutaneous T 54 Metastatic colorectal cancer 54 Hepatocellular Carcinoma HCC 54 chronic lymphocytic leukemia CLL 54 gemcitabine carboplatin 54 pediatric malignancies 54 tumor xenograft models 54 factor receptor 54 chemotherapeutic regimens 54 AVODART 54 decitabine 54 biliary tract cancer 54 lymphoid malignancies 54 ALND 54 metastatic CRC 54 HER2 positive metastatic 54 H. pylori eradication 54 aplastic anemia AA 54 Mitomycin C 54 Cell Lymphoma 54 renal carcinoma 54 lymphocytosis 54 chlamydial infection 54 docetaxel 54 chemoembolization 54 Hepatocellular Carcinoma 54 aromatase inhibitor therapy 54 EUS FNA 54 T2DM 54 Relapsed Refractory 54 Hodgkin lymphoma HL 54 pegfilgrastim 54 multiple myeloma MM 54 binds selectively 54 confidence interval #.#-#.# 54 primary hypercholesterolemia 54 fulvestrant 54 elevated CRP 54 FOLFOX 54 preoperative radiotherapy 54 unresectable Stage III 54 ALCL 54 pheochromocytomas 54 IDH mutations 54 Hashimoto thyroiditis 54 neuroendocrine carcinoma 54 endometrioid 54 exemestane 54 squamous 54 metastatic cancers 54 factor receptor EGFR 54 ZOLINZA 54 papillary 54 leukemia APL 54 hormone refractory 54 daunorubicin 54 MALT lymphoma 54 WT1 54 Bezielle 54 Pharmacokinetics PK 54 BRCA mutation 54 exemestane Aromasin 54 mycophenolate mofetil 54 prostate cancer AIPC 54 TYKERB 54 metastatic prostate 54 docetaxel prednisone 54 ELOXATIN 54 hormone deprivation 54 refractory NSCLC 54 chemotherapy FOLFOX 54 dasatinib Sprycel 54 nucleoside analogue 54 concurrent chemoradiation 54 prostate lung 54 Velcade bortezomib 54 STRIDE PD 54 virologic failure 54 pancreatic cancers 54 HBeAg positive patients 54 recurrent colorectal cancer 54 sorafenib Nexavar ® 54 DFMO 54 metastatic lesions 54 myelodysplastic myeloproliferative diseases 54 colorectal tumors 54 thyrotoxicosis 54 cell lymphoma CTCL 54 Degarelix 54 ixabepilone 54 diagnostic biomarker 54 chemopreventive agent 54 Dapagliflozin 54 heavily pretreated 54 Invasive Breast Cancer 54 invasive aspergillosis 54 pancreatic prostate 54 neoplasm 54 squamous cell lung cancer 54 squamous cell cancers 54 intravesical therapy 54 sorafenib 54 trastuzumab Herceptin ® 54 anti EGFR antibody 54 BENICAR HCT 54 Fludara 54 PNET 54 corticosteroid dexamethasone 54 systemic lupus erythematosus SLE 54 PI3K Akt 54 basal cell cancers 54 fluorouracil leucovorin 54 hamartomas 54 parathyroid carcinoma 54 androgen receptor AR 54 advanced metastatic renal 54 antiestrogen therapy 54 erlotinib 54 metastatic CRPC 54 mutational status 54 RoACTEMRA 54 GW# [003] 54 SPRYCEL ® 54 Fludara ® 54 Azacitidine 54 lipid abnormalities 54 Pertuzumab 54 abacavir lamivudine 54 ABVD 54 B Cell Lymphoma 54 adjuvant hormonal therapy 54 subtype 54 imatinib resistant 54 ACTEMRA TM 54 allogeneic stem cell 54 activating mutations 54 AGTR1 54 papillary RCC 54 prostate cancer PCa 54 para aortic 54 gastrointestinal stromal tumors GISTs 54 benign proliferative breast 54 CLL SLL 54 radiosensitive 54 conjugated equine estrogens 54 seminoma 54 surgically resectable 54 mitoxantrone chemotherapy 54 advanced pancreatic neuroendocrine 54 bladder prostate 54 underwent prostatectomy 54 benign breast 54 osteopenic 54 malignancies 54 metastatic liver 54 alefacept 54 malignant lesions 54 NAFLD 54 venous thromboembolic events 54 cell adhesion molecule 54 refractory AML 54 epirubicin cyclophosphamide 54 immunohistochemical staining 54 histological subtypes 54 leukaemias 54 PEGINTRON TM 54 MGd 54 myeloproliferative disorders 54 grade glioma 54 ovarian cancers 54 irreversible inhibitor 54 interleukin IL -# 54 Endometrial cancer 53 TAXOTERE R 53 gastrointestinal cancers 53 biliary cancer 53 Temsirolimus 53 TNF blocker therapy 53 Tavocept 53 solar keratosis 53 Myelofibrosis 53 prostate cancer HRPC 53 Gefitinib 53 estramustine 53 sunitinib 53 anti angiogenic therapy 53 FGFR2 53 Aflibercept 53 Estrogens 53 prostate colon 53 GSTT1 53 antitumor effect 53 TACE 53 Paraplatin ® carboplatin 53 deCODE BreastCancer 53 adjuvant tamoxifen 53 EGFR tyrosine kinase inhibitors 53 prior chemotherapy regimens 53 acid phosphatase PAP 53 localized renal 53 promoter methylation 53 cutaneous T 53 IV NSCLC 53 debulking surgery 53 ara C 53 relapsing remitting MS RRMS 53 octreotide LAR 53 Akt activation 53 efalizumab 53 MetS 53 cetuximab Erbitux R 53 lumbar spine BMD 53 TORISEL 53 Gemzar ® 53 HMG CoA reductase inhibitors 53 5 FU leucovorin 53 SUTENT 53 #.#ng/ml 53 Femara letrozole 53 previously untreated follicular 53 intraepithelial neoplasia 53 ocular melanoma 53 transitional cell carcinoma 53 invasive coronary angiography 53 cell lymphoma ALCL 53 Hormonal therapy 53 chronic HBV infection 53 premalignant 53 ALT normalization 53 esophageal squamous cell carcinoma 53 relapsed Acute Myeloid 53 PCNSL 53 oblimersen 53 Flu Cy 53 metastatic androgen independent 53 hypermethylated 53 mitoxantrone 53 poor metabolizers 53 Camptosar ® 53 ductal lobular 53 cytoreductive surgery 53 beta carotene supplementation 53 chemo radiotherapy 53 gynecologic malignancy 53 refractory chronic myeloid 53 pelvic malignancies 53 endometrial 53 colorectal neoplasia 53 EGFR protein 53 postmenopausal hormone 53 KRAS oncogene 53 IV bisphosphonates 53 lobular 53 squamous cell histology 53 subclinical hyperthyroidism 53 sentinel nodes 53 Menopausal hormone therapy 53 trans retinoic acid 53 curable cancers 53 standard chemotherapy regimen 53 malignant growths 53 postmenopausal osteoporotic women 53 CR nPR 53 lung metastasis 53 Venous thromboembolism 53 Anaplastic 53 PCA3 scores 53 low dose cytarabine 53 epithelial cancers 53 etoposide 53 vinca alkaloids 53 rFSH 53 assessing T DM1 53 K ras 53 nab paclitaxel 53 Oxaliplatin 53 eosinophilic pneumonia 53 forodesine 53 Trastuzumab Herceptin 53 Waldenstrom macroglobulinemia 53 gestational hypertension 53 chemotherapy regimen 53 axillary lymph node 53 CHOP chemotherapy 53 TEMODAL 53 nonfatal MI 53 leukemia ALL 53 essential thrombocythemia 53 clodronate 53 LHRH analogues 53 papillary thyroid cancer 53 testicular cancers 53 5 fluorouracil leucovorin 53 mammographic density 53 Platinol 53 CsA 53 HER2 neu 53 fluorouracil 53 urine cytology 53 APTIVUS r 53 Bortezomib 53 olaparib 53 TIMP 53 ovarian uterine 53 Natalizumab 53 aromatase inhibitors AIs 53 Docetaxel 53 anti androgen 53 refractory cutaneous T 53 SLN biopsy 53 TT genotype 53 non splenectomized 53 Ph + ALL 53 Androgen deprivation therapy 53 choriocarcinoma 53 squamous cell carcinomas 53 relapsed leukemia 53 doublet chemotherapy 53 thyroglobulin 53 neoplasias 53 atrophic gastritis 53 gastrointestinal malignancies 53 BRAF V# mutation 53 Carboplatin 53 Raf MEK ERK 53 Zolinza 53 urothelial cancer 53 BRCA1 mutations 53 Epstein Barr virus EBV 53 MTHFR 53 progesterone receptor 53 COPAXONE R 53 temozolomide TMZ 53 remission induction 53 HBsAg 53 lung carcinomas 53 hormone LHRH agonist 53 systemic anaplastic large 53 gemcitabine 53 Glioblastoma Multiforme GBM 53 prognostic marker 53 ovarian endometrial 53 asymptomatic carotid stenosis 53 thyroid stimulating hormone 53 grade dysplasia 53 papillary carcinoma 53 refractory ovarian cancer 53 invasive ductal breast cancer 53 prognostic biomarker 53 subtrochanteric 53 oral antidiabetic medication 53 vWD 53 neuroendocrine cancers 53 ERCC1 53 underwent resection 53 c KIT 53 Renal Cell Carcinoma RCC 53 cirrhosis liver failure 53 serum PSA 53 neratinib 53 LCIS 53 HER2 protein 53 nonmelanoma skin cancer 53 pancreatic colon 53 Selective Internal 53 Mimpara 53 opioid induced constipation OIC 53 TRAIL R1 53 MAGE A3 53 hormonally sensitive 53 ribavirin therapy 53 MGUS 53 IFN beta